Taiwan Advance Bio-Pharmaceutical

What Taiwan Advance Bio-Pharmaceutical does

Taiwan Advance Bio-Pharmaceutical Inc. (TABP, ticker 4186 on Taiwan OTC, 台灣尖端先進生技醫藥股份有限公司) is a publicly listed biotechnology company founded in 2000 as Taiwan's first biotech spin-off from the government-run Development Center for Biotechnology (DCB), inheriting 7 key technologies, 34 products, and 46 patent licenses. The company operates an integrated portfolio spanning three core platforms: precision diagnostics (food safety ELISA kits, lateral flow rapid tests, and chemical reagents for drug residues and mycotoxins; drug abuse rapid tests and TFDA-certified confirmation laboratory services), regenerative medicine and cell therapy (umbilical cord blood and adult stem cell banking under GTP certification, autologous bone marrow mesenchymal stem cell treatment for spinal cord injury and degenerative arthritis under Taiwan's 特管辦法 special regulatory framework, and the TAT-HOXB4/Hb4Cord hematopoietic stem cell expansion platform), and emerging cosmeceutical applications (INCI-certified CYTORUMM exosome raw material and finished skincare brands 詩特膚奇姬 and 蕾蒔莉 REJOLI).

The company monetizes through a mix of one-time product sales (food safety test kits, drug rapid tests), recurring storage fees (stem cell banking subscriptions on annual cadence), professional services (CRDMO cell preparation, judicial forensics, workplace drug testing), and hardware sales (cosmeceutical products). Distribution runs through six Taiwan regional offices (New Taipei, Taipei, Taoyuan, Taichung, Tainan, Kaohsiung) and an international distributor network spanning China (40%), Southeast Asia (35%), Middle East (10%), East Asia (5%), and North America (5%). The institutional customer base includes Taiwan's National Police Agency and High Prosecutors Office, multi-hospital cell therapy networks (Linkou Chang Gung, Taichung VGH, Hualien Tzu Chi, Guangtian General, and others), and B2B buyers in food manufacturing, aquaculture, transportation, and logistics.

Recent strategic momentum centers on regulatory-driven testing demand (saliva rapid drug test launched nationwide November 2025 under new police enforcement policy, driving 60% YoY growth in drug evidence testing cases), international expansion into South Asia and ASEAN via 'AI Smart Transformation' positioning, and the Greater China/Asia-Pacific Cell Factory Output partnership signed with Jian Duan Xi Biotechnology in May 2023. The company reports FY2025 net profit of NT$28.047 million (EPS NT$0.31), up 22.6% from NT$22.875 million (EPS NT$0.25) in FY2024, with detection services cited as the primary growth driver.

Name

Taiwan Advance Bio-Pharmaceutical

Legal name

台灣尖端先進生技醫藥股份有限公司

Website

https://biotest.com.tw

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Taiwan Advance Bio-Pharmaceutical Inc. (Ticker 4186) is a Taiwan-based biotech company providing food safety diagnostic kits, drug abuse testing services, stem cell banking, and cell therapy preparation for government agencies, hospitals, and food manufacturers across Asia-Pacific markets.

Ownership category

akta.pro rank

Product category

Biotechnology Diagnostics and Life Sciences

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Food safety testing
• Drug abuse detection
• Stem cell banking
• Cell therapy services
• Diagnostic test kits

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Cell Preservation and Banking Services: Stem cell banking services including umbilical cord blood, cord tissue, autologous immune cells, peripheral blood stem cells, adipose-derived stem cells, bone marrow stem cells, and autologous fibroblasts. Long-term recurring revenue model from storage fees.
2. Food Safety Detection Products and Services: ELISA test kits, rapid test strips, and chemical test reagents for food safety detection covering drug residues, veterinary antibiotics, mycotoxins, and foodborne pathogens. Revenue from product sales and laboratory testing fees.
3. Drug and Drug Abuse Testing Services: Complete drug testing ecosystem including saliva rapid tests, urine rapid tests, drug evidence confirmation testing, and judicial forensics. Revenue from government contracts, enterprise employee testing programs, and reagent sales.
4. Cell Therapy and Contract Manufacturing (CRDMO): Cell therapy preparation services under Taiwan's Special Act for cell therapy (特管辦法), including mesenchymal stem cell treatment for spinal cord injury, degenerative arthritis, and cartilage defects. CDMO/CRDMO services for cell preparation and testing technology.
5. Cosmeceutical and Exosome-Based Products: INCI-certified exosome raw materials (CYTORUMM) and finished cosmetic products under brands '詩特甯奇姬' and '蕾蕎莉REJOLI' for skincare and hair care applications.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Taiwan Advance Bio-Pharmaceutical develops, manufactures, and sells diagnostic test kits (ELISA, lateral flow rapid tests, chemical reagents) for food safety and drug abuse detection, and provides related laboratory confirmation services. The company also operates stem cell banking and storage services for cord blood, cord tissue, adipose, bone marrow, and adult-derived cells, along with GTP-certified cell therapy preparation services under Taiwan's Special Regulatory Measures. Additional offerings include genetic/HLA typing, exosome-based cosmeceutical ingredients (CYTORUMM/INCI), and TAT-HOXB4 hematopoietic stem cell expansion platform technology.

Product overview

Taiwan Advance Bio-Pharmaceutical is a biotechnology company offering an integrated portfolio of diagnostic products and life science services. The core products include Food Safety Diagnostic Kits (ELISA kits, Rapid Test kits, and Chemical Test kits) for detecting drug residues and biotoxins in food; Drug/Abused Drugs Rapid Tests for urine, saliva, and drug material identification; and Stem Cell Banking Services for storing various stem cell types. The company also provides Cell Therapy Services under Taiwan's Special Regulation (特管辦法) for bone marrow stem cell treatments, CIK immune cell therapy, and adipose-derived stem cell applications. Supporting services include Genetic Testing Services, a TAT-HOXB4/Hb4Cord protein drug development platform for hematopoietic stem cell expansion, and laboratory testing services. Recent additions include CYTORUMM exosome ingredients for cosmeceuticals and the 詩特甯奇姬 and 蕾蕎莉REJOLI skincare product lines.

Differentiator

Problem solved

Functional benefit

Brands

• 詩特甯奇姬 (Stenike): Skincare and repair product line using Ganoderma exosomes and polysaccharides as base ingredients, developed by TABP for the domestic market.
• 蕾蕎莉 REJOLI
• 詩特甯 (Stenike)
• 日曜肌泌

Products and services

• Food Safety Diagnostic Kits ELISA kits, lateral flow rapid test kits, and chemical test reagents for detecting drug residues (e.g., ractopamine, enrofloxacin), veterinary antibiotics, mycotoxins (aflatoxin), and foodborne pathogens. Covers meat, dairy, eggs, honey, feed, and aquaculture products. For food manufacturers, aquaculture farms, and food testing laboratories.
• Drug Abuse Rapid Test Kits Rapid test kits covering urine drug panels, saliva drug panels (including saliva rapid test for drug-driving enforcement), and drug material identification. Detects methamphetamine, morphine, cannabis, ketamine, benzodiazepines, K2, MDPV, and new psychoactive substances. Sold to government agencies, law enforcement, and enterprises.
• Stem Cell Banking Services Long-term cryogenic storage services for newborn (umbilical cord blood, umbilical cord) and adult (autologous immunocytes, peripheral blood stem cells, adipose-derived stem cells, bone marrow stem cells, fibroblasts) cell types. Annual subscription-based storage fees.
• Cell Therapy Services (Special Act for Cell Therapy, 特管辦法) GTP-certified cell preparation services for autologous bone marrow mesenchymal stem cell treatment of spinal cord injury, degenerative arthritis, and cartilage defects; CIK immune cell therapy for cancer; and adipose-derived stem cell therapy for wound healing. Provided to approved medical institutions in Taiwan under the Special Act for Cell Therapy.
• Genetic Testing Services Disease gene detection (MTHFR), pathogen nucleic acid testing (HIV/HCV/HBV), HPV typing, HLA sequencing-based typing for transplantation matching, and biosafety testing (Mycoplasma detection). For hospitals, transplant programs, and clinical laboratories.
• TAT-HOXB4 / Hb4Cord Stem Cell Expansion Platform Proprietary protein drug development platform using TAT-HOXB4 recombinant protein for ex vivo expansion of CD34+CD38- hematopoietic stem cells from cryopreserved cord blood. Non-viral delivery with high expansion fold and viability. Supported by multi-country patents.
• CYTORUMM Exosome Ingredient INCI-certified exosome raw material (CYTORUMM) obtained April 2025, derived from Ganoderma lucidum exosomes and polysaccharides. Sold as a B2B ingredient to cosmetic brands and skincare product manufacturers.
• COVID-19 Diagnostic Tests SARS-CoV-2 rapid antigen tests, antibody rapid tests, and ELISA kits developed from technology transferred from NHRI and IPM of NDMC. For public health screening and clinical diagnosis.
• Cosmeceutical Product Lines (Stenike 詩特薇奇姬 and REJOLI 蕾蒄莉) Finished skincare and hair care products under brands 詩特薇奇姬 (Stenike) and 蕾蒄莉 (REJOLI) using Ganoderma exosome and polysaccharide base ingredients, including repair series, essence serums, hair care essence, and daily soap products.
• Drug Testing Laboratory Services Laboratory testing services for urine drug confirmation (up to 76+ identification items), drug material identification (up to 697 qualitative items), and quantitative analysis for 9 substances. Certified by TFDA and appointed by High Prosecutors Office.

Quantifiable outcome

• Drug evidence testing cases in Year 114 grew 60% year-over-year, driving related testing revenue up 15%
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• Jian Duan Xi Biotechnology Co., Ltd. (尖端亞細生技股份有限公司)coreStrategic or Co-development Partner · 18 May 2023Strategic partnership for 'Cell Factory Output' project targeting Greater China and Asia-Pacific markets. TABP provides cell culture, cell preservation services, laboratory SOP, process, GTP/GMP QA/QC factory output services. Jian Duan Xi, invested in by Clouded Leopard Energy founder Zhang Jianwei, handles market development, investment partner sourcing, and integration services across high-end medical clinics, AI-powered cell labs, regenerative and preventive medicine, clinic/pharmacy chains, and migrant worker healthcare. This represents Taiwan's first integrated upstream-downstream biotech industry cross-domain business model.
• Guangtian General Hospital (光田綜合醫院)coreStrategic or Co-development PartnerCell therapy collaboration partner for autologous bone marrow mesenchymal stem cell treatment. TABP provides GTP-certified cell preparation; hospital provides clinical treatment. Landmark spinal cord injury and degenerative arthritis treatment cases documented. Collaborative clinical case shared publicly at press events.
• Hualien Tzu Chi Hospital (花蓮慈濟醫院)coreStrategic or Co-development PartnerCell therapy collaboration partner. TABP is the first in Taiwan to receive TFDA approval for mesenchymal stem cell therapy for spinal cord injury. Hualien Tzu Chi serves as the medical institution partner, providing clinical treatment under 特管辦法. First Taiwan spinal cord injury stem cell therapy case was conducted at this hospital.
• Linkou Chang Gung Memorial Hospital, Taichung VGH, Taichung Tzu Chi, Dalin Tzu Chi, Changhua Show Chan, Yuan Guo Hospital, Taipei Medical University Hospital, Hualien Tzu Chi, Kaohsiung Armed Forces General HospitalcoreStrategic or Co-development PartnerMulti-hospital cell therapy network. TABP serves as cell preparation provider for multiple approved 特管辦法 cell therapy plans across Taiwan, including autologous bone marrow stem cells for spinal cord injury, degenerative arthritis, and cartilage defects. Network spans major medical centers throughout Taiwan.
• Academic and Research Institutions (Academia Sinica, National Taiwan University, National Central University, China Academy of Chinese Medical Sciences)supportingTechnology or IntegrationCollaborative antigen development and research partnerships with leading Taiwanese and Chinese academic institutions for monoclonal/polyclonal antibody platform development and diagnostic technology advancement.
• Cosmeceutical Brand Partners (詩特甯奇姬, 蕾蕎莉REJOLI)supportingChannel Partner/ Reseller/ DistributorCo-development partnerships with cosmetic brands for exosome-based skincare and hair care products. TABP provides INCI-certified exosome raw materials (CYTORUMM) and Ganoderma lucidum exosome formulations. Partners develop and market finished products under their own brand names.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• SGS: Global testing, inspection, and certification company providing food safety and pharmaceutical testing services. Competes with TABP at the international B2B testing services level, particularly in Southeast Asia where TABP sells 35% of its international kit volume.
• Eurofins Scientific: Global leader in food safety testing services with comprehensive laboratory network. While much larger and broader, Eurofins overlaps with TABP's food/drug residue testing capabilities and represents the type of scale player that competes for multinational food exporter accounts.
• bioMérieux: French in-vitro diagnostics company with broad microbiology and clinical diagnostics portfolio. Overlaps with TABP's diagnostic test kit business in terms of customer type (clinical labs, food industry) and product category (immunoassays, rapid tests).
• QuidelOrtho: US diagnostics company with established rapid test kit and immunoassay product lines. Represents the type of larger, well-capitalized competitor that competes in the same lateral flow/ELISA category where TABP operates.

Direct peers

• Cryo-Cell International: US-listed cord blood and tissue banking company with a comparable stem cell storage subscription model. Provides a useful benchmark for unit economics, customer acquisition cost, and recurring revenue stability in the cord blood banking category.
• Neogen Corporation: US-based food safety diagnostics company producing ELISA kits, lateral flow tests, and laboratory testing services for food pathogen and residue detection. Direct product portfolio overlap with TABP's food safety diagnostic kits business, though at much larger scale.
• China Cord Blood Corporation: Cord blood banking operator in China—the same core recurring-revenue cell preservation business model as TABP's stem cell banking services. Both face similar regulatory environments and depend on consumer/parent adoption of newborn cell storage.
• Standard Diagnostics: Korean in-vitro diagnostics manufacturer focused on rapid test kits for infectious disease, drug abuse, and food safety—closely matching TABP's lateral flow/ELISA product portfolio. Both companies serve similar B2B institutional channels (government, hospitals, food manufacturers) across Asia.

Emerging players

• Mesoblast: Australia-listed cell therapy company focused on mesenchymal stem cell therapies for inflammatory conditions. Provides a benchmark for MSC-based therapy commercialization, regulatory pathway, and indication strategy relevant to TABP's cell therapy business under 特管辦法.
• GenScript Biotech: Hong Kong-headquartered biotech with cell therapy, gene synthesis, and life science research services. Comparable geographic origin (Greater China/Taiwan biotech ecosystem) and overlapping cell therapy and biologics platform capabilities with TABP.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taiwan Advance Bio-Pharmaceutical